1.Seligmann JF, Morton D, Elliott F, Handley K, Gray R, Seymour M, Glimelius B, Magill L, Williams CJM, Quirke P, Bottomley D, Wood HM, Murakami K, Beggs AD, West NP; FOxTROT Collaborative Group.. Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population.. Annals of Oncology. 2025
2.Avallone A, Giuliani F, De Stefano A, Santabarbara G, Nasti G, Montesarchio V, Rosati G, Cassata A, Leo S, Romano C, Tamburini E, Silvestro L, Lotesoriere C, Nappi A, Santini D, Petrillo A, Colombo A, Febbraro A, Leone A, Mannavola F, Laterza MM, Izzo F, Sobrero A, Delrio P, Giannarelli D, Budillon A.. Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial.. Journal of Clinical Oncology. 2025
3.Ciracì P, Germani MM, Pietrantonio F, Manca P, Lonardi S, Busico A, Bergamo F, Burgio V, Mannavola F, Di Donato S, Fenocchio E, Palermo F, Capone I, De Grandis MC, Pella N, Scartozzi M, Antonuzzo L, Passardi A, Claravezza M, Salvatore L, Tamberi S, Randon G, Conca E, Conca V, Antoniotti C, Moretto R, Masi G, Boni L, Rossini D, Cremolini C; GONO Foundation Investigators.. Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO.. Annals of Oncology. 2026
I link ai libri possono contenere un codice affiliato Amazon: in qualità di affiliato, ECM Finder potrebbe ricevere una commissione sugli acquisti idonei, senza alcun costo aggiuntivo per te. I link ai paper rimandano alla fonte scientifica (DOI, versione open-access o ricerca accademica).